Live Market Updates
Market headlines from global newswires, updated twice daily at 8:00 AM and 1:00 PM New York time.
45 articles
Live UpdateThe Next AI Infrastructure Winner Isn't a Memory Stock. It's This.
As AI data centers expand, Seagate Technology is positioned as a critical infrastructure provider for bulk storage needs. The company reported 48% revenue growth to $3.63 billion and achieved record operating margins of 34.6%, driven by demand for its HAMR hard drive technology. While the stock has surged over 200% in the past year, investors should consider risks including high expectations, potential order delays, and supply chain challenges.
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Interim analysis of the Phase 3 DASL-HiCaP trial shows that darolutamide combined with androgen deprivation therapy and radiation therapy reduces the risk of metastasis or death by 58% in high-risk prostate cancer patients, achieving a 4-year metastasis-free survival rate of 95% versus 88% with placebo. The safety profile was consistent with previous studies.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Zymeworks presented Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate, showing a confirmed objective response rate of 64.5% at the 6.4 mg/kg dose in heavily pretreated patients with platinum-resistant ovarian cancer. The drug demonstrated meaningful activity across all FRα expression levels with a favorable tolerability profile, particularly at the lower dose, supporting continued clinical development.
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Immatics announced updated clinical trial data for its PRAME-targeting therapies at the 2026 ESMO Annual Meeting. IMA402 bispecific achieved a 32% confirmed objective response rate in PRAME-high melanoma patients with a 12.5-month median duration of response and 91% one-year overall survival rate. IMA203CD8 cell therapy demonstrated a 55% response rate in gynecologic cancers at clinically relevant doses with an 8.4-month median duration of response. Both therapies showed favorable safety profiles, supporting continued development across multiple solid tumor indications.
Live UpdateHere's the AI Chip Stock That Hedge Funds Are Loading Up On
Hedge funds dramatically shifted their stance on Broadcom in September, flipping from shorting the stock in August to making it one of their most-held positions. The AI chipmaker's impressive Q3 earnings—with AI semiconductor revenue surging 221% year-over-year to $16.7 billion—drove the reversal. Despite concerns about valuation after a 59% annualized return over three years, analysts view Broadcom as attractive at current valuations with a forward P/E of 19 and strong growth projections through 2028.
Live UpdateIs It Too Late to Buy SpaceX Stock After Its Monster Third-Quarter Earnings Report? Here's the Answer.
SpaceX reported strong Q3 2026 earnings with $14.5B revenue (beating $12.7B estimates) and $4.4B net income. The AI division generated $7.6B in revenue, more than half of total revenue, up from $813M year-over-year. While the stock has experienced significant volatility since its June IPO, analysts suggest long-term investors with conviction should not hesitate to buy, as the company is still in early stages of capturing its $26.5T AI-focused total addressable market.
Live UpdateRyder: 3 Key Takeaways for Long-Term Investors
Ryder raised its 2026 comparable earnings per share forecast to $14.85-$15.05, driven by a strategic shift toward asset-light operations. Supply Chain Solutions and Dedicated Transportation now represent 60% of expected 2026 revenue, up from 44% in 2018. With $4.5 billion in available capital and commercial rental fleet utilization at 77%, management is positioned to fund growth, return capital to shareholders, and capitalize on stabilizing freight market conditions.
Live UpdateIf I Could Tell Every Investor 1 Thing About Stock Market Crashes, It Would Be This
The article emphasizes that market corrections and bear markets are normal and healthy parts of long-term investing. Historical data shows corrections occur roughly every other year, with bear markets averaging 36% losses lasting about 13 months, while bull markets last over 5 years with average returns of 182.5%. Long-term investors should expect pullbacks, maintain their positions, and view crashes as buying opportunities rather than reasons to panic.
Live UpdateOpenAI Nears $1.25 Trillion Valuation. What That Tells Investors Ahead of a Potential 2027 IPO.
OpenAI is closing a $30 billion funding round at a $1.25 trillion valuation, down from its initial $1.5 trillion target. The company plans to go public in 2027, waiting for market conditions to improve after rival Anthropic's expected November IPO at a $2 trillion valuation. The funding round signals continued investor interest in AI despite recent sector fatigue.
Start Your Trading Journey
Register, fund, and start trading today, your path to smarter investing begins here.
